Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quisovalimab (Primary) ; Corticosteroids; Remdesivir
  • Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia; Cytokine release syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Aevi Genomic Medicine

Most Recent Events

  • 01 Feb 2022 Results published in the Journal of Clinical Investigation
  • 13 May 2021 According to a Cerecor media release, CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 ARDS
  • 02 Mar 2021 Primary endpoint (Proportion of patient alive and free of respiratory failure) has been met, according to a Cerecor media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top